Insulet Corporation (PODD) is a publicly traded Healthcare sector company. As of May 21, 2026, PODD trades at $157.13 with a market cap of $10.56B and a P/E ratio of 36.47. PODD moved +1.29% today. Year to date, PODD is -44.77%; over the trailing twelve months it is -52.18%. Its 52-week range spans $145.59 to $354.88. Analyst consensus is buy with an average price target of $262.52. Rallies surfaces PODD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Insulet Slides After Q1 Beat as Omnipod 5 Class I Recall Overhang Persists: Insulet shares fell as investors digested first-quarter 2026 results released May 6, 2026, despite an earnings and revenue beat. The decline is being amplified by ongoing scrutiny of a Class I recall involving certain Omnipod 5 pod lots tied to potential insulin under-delivery risk.
| Metric | Value |
|---|---|
| Price | $157.13 |
| Market Cap | $10.56B |
| P/E Ratio | 36.47 |
| EPS | $4.30 |
| Dividend Yield | 0.00% |
| 52-Week High | $354.88 |
| 52-Week Low | $145.59 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.90B |
| Net Income | $302.80M |
| Gross Margin | 71.01% |
23 analysts cover PODD: 0 strong buy, 18 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $262.52.